Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
French and Malaysian authorities are investigating Grok for generating sexualized deepfakes - 2Vote In favor of Your Favored Web based Dating Application
- 3The 10 Most Progressive Logical Disclosures
- 4Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- 5Nature's Treats: 10 Organic products That Lift Prosperity
- See tonight’s solar storm unfold across the world
- Should you get an RSV vaccine this fall? What to know and where to get a shot
- A Gustav Klimt painting is now the most expensive piece of modern art sold at auction. The fascinating history behind the $236 million 'Portrait of Elisabeth Lederer.'
- Step by step instructions to Pick an Incineration Urn: Variables to Consider
- Vote In favor of Your Favored Shimmering Water
- Eleven Creations And Developments That Steered History
- Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- The Delight of Perusing: Book Proposals for Each Class
